Skip to main content

Advertisement

Advertisement

World

Delta COVID-19 variant becoming globally dominant, WHO official says

Delta COVID-19 variant becoming globally dominant, WHO official says

A logo is pictured outside a building of the World Health Organization (WHO) in Geneva on Apr 6, 2021, during an executive board meeting on updates on the COVID-19 outbreak. (File photo: Reuters/Denis Balibouse)

GENEVA: The Delta variant of the coronavirus, first identified in India, is becoming the globally dominant variant, the World Health Organization's (WHO) chief scientist said on Friday (Jun 18).

Soumya Swaminathan also voiced disappointment in the failure of CureVac's COVID-19 vaccine candidate in a trial to meet the WHO's efficacy standard, in particular as highly transmissible variants boost the need for new, effective shots.

Britain has reported a steep rise in infections with the Delta variant, while Germany's top public health official predicted it would rapidly become the dominant variant there despite rising vaccination rates.

The Kremlin blamed a surge in COVID-19 cases on reluctance to have vaccinations and "nihilism" after record new infections in Moscow, mostly with the new Delta variant, fanned fears of a third wave.

"The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility," Swaminathan told a news conference.

READ: Moscow COVID-19 cases soar to record as mayor blames Delta variant

READ: Delta variant fuelled 50 per cent rise in England's COVID-19 prevalence, study says

Coronavirus variants were cited by CureVac when the German company this week reported that its vaccine proved only 47 per cent effective at preventing disease, shy of the WHO's 50 per cent benchmark.

The company said it documented at least 13 variants circulating within its study population.

Given that similar mRNA vaccines from Pfizer-BioNTech and Moderna posted efficacy rates topping 90 per cent, Swaminathan said that the world had been expecting more from CureVac's candidate.

"Just because it's another mRNA vaccine, we cannot presume all mRNA vaccines are the same, because each one has a slightly different technology," Swaminathan said, adding that the surprise failure underscored the value of robust clinical trials to test new products.

WHO officials said that Africa remains an area of concern, even though it accounts for only around 5 per cent of new global infections and 2 per cent of deaths.

New cases in Namibia, Sierra Leone, Liberia and Rwanda have doubled in the last week, WHO emergencies programme head Mike Ryan said, while vaccine access remains minuscule.

"It's a trajectory that is very, very concerning," Ryan said. "The brutal reality is that in an era of multiple variants, with increased transmissibility, we have left vast swathes of the population, the vulnerable population of Africa, unprotected by vaccines."

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/kg

Advertisement

Also worth reading

Advertisement